Amphastar Pharmaceuticals, Inc. $AMPH Stock: Bridge City Capital LLC Boosts Position

Key Points

• Bridge City Capital increased its Amphastar Pharmaceuticals position by 13.3% in the third quarter, bringing its holdings to 383,901 shares valued at approximately $9.9 million. Institutional investors collectively own 65.09% of the company.
• Amphastar reported quarterly earnings of $0.91 per share, exceeding the $0.62 analyst consensus, while revenue of $183.9 million also surpassed expectations.
• Despite the earnings beat, analyst sentiment remains cautious: seven analysts rate the stock Hold and one rates it Sell, resulting in an average “Reduce” rating and a $22.50 price target versus a recent share price of $27.72.

Bridge City Capital LLC grew its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 13.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 383,901 shares of the company's stock after purchasing an additional 45,193 shares during the quarter. Amphastar Pharmaceuticals makes up about 2.1% of Bridge City Capital LLC's investment portfolio, making the stock its 6th largest position. Bridge City Capital LLC owned 0.90% of Amphastar Pharmaceuticals worth $9,908,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 10.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,762 shares of the company's stock worth $207,000 after buying an additional 745 shares during the period. Nisa Investment Advisors LLC increased its holdings in Amphastar Pharmaceuticals by 183.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,422 shares of the company's stock valued at $37,000 after purchasing an additional 920 shares in the last quarter. Bessemer Group Inc. increased its position in Amphastar Pharmaceuticals by 1.0% in the first quarter. Bessemer Group Inc. now owns 122,046 shares of the company's stock worth $2,391,000 after buying an additional 1,156 shares during the period. Quantbot Technologies LP acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at about $39,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Amphastar Pharmaceuticals during the third quarter worth $56,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $27.72 on Monday. The business's 50 day moving average is $24.76 and its two-hundred day moving average is $22.31. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.18 billion, a PE ratio of 16.40, a price-to-earnings-growth ratio of 5.41 and a beta of 0.90. Amphastar Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $29.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. The business had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. Equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating on the stock in a research report on Friday, August 7th. Barclays boosted their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 18th. Wells Fargo & Company boosted their price target on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Amphastar Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Finally, Zacks Research upgraded shares of Amphastar Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 21st. Seven analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and an average price target of $22.50.

Insider Activity at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the sale, the executive vice president owned 169,203 shares of the company's stock, valued at $4,050,719.82. The trade was a 5.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO William J. Peters sold 8,180 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $22.48, for a total value of $183,886.40. Following the completion of the sale, the chief financial officer owned 172,846 shares in the company, valued at approximately $3,885,578.08. The trade was a 4.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 33,479 shares of company stock valued at $763,922. Insiders own 29.60% of the company's stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.